Please use this identifier to cite or link to this item:
https://hdl.handle.net/10316/106523
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Silva, Lígia C. Gomes da | - |
dc.contributor.author | Kepp, Oliver | - |
dc.contributor.author | Kroemer, Guido | - |
dc.date.accessioned | 2023-04-06T09:35:39Z | - |
dc.date.available | 2023-04-06T09:35:39Z | - |
dc.date.issued | 2020-10-27 | - |
dc.identifier.issn | 2162-4011 | pt |
dc.identifier.uri | https://hdl.handle.net/10316/106523 | - |
dc.description.abstract | In September 2020, the Japanese government approved cetuximab saratolacan (previously known as RM-1929, commercial name: Akalux) for the treatment of unresectable locally advanced or recurrent head and neck cancer. Cetuximab saratolacan is a chemical conjugate of the photosensitizer IR700 with cetuximab, which targets EGFR. The treatment consists in the intravenous injection of cetuximab saratolacan, which binds to head and neck cancer cells expressing high levels of EGFR, followed by illumination of the tumor with red light (690 nm) for photodynamic therapy. This approach causes immunogenic cell death in malignant tissues, thus triggering a potent anticancer immune response. | pt |
dc.language.iso | eng | pt |
dc.publisher | Taylor & Francis | pt |
dc.rights | openAccess | pt |
dc.rights.uri | http://creativecommons.org/licenses/by-nc/4.0/ | pt |
dc.subject | Cetuximab saratolacan | pt |
dc.subject | photosensitizer IR700 | pt |
dc.subject | EGFR | pt |
dc.subject | immunogenic cell death | pt |
dc.subject | head and neck cancer | pt |
dc.subject.mesh | Humans | pt |
dc.subject.mesh | Immunogenic Cell Death | pt |
dc.subject.mesh | Immunotherapy | pt |
dc.subject.mesh | Neoplasm Recurrence, Local | pt |
dc.subject.mesh | Phototherapy | pt |
dc.subject.mesh | Photochemotherapy | pt |
dc.title | Regulatory approval of photoimmunotherapy: photodynamic therapy that induces immunogenic cell death | pt |
dc.type | article | - |
degois.publication.firstPage | 1841393 | pt |
degois.publication.issue | 1 | pt |
degois.publication.title | OncoImmunology | pt |
dc.peerreviewed | yes | pt |
dc.identifier.doi | 10.1080/2162402X.2020.1841393 | pt |
degois.publication.volume | 9 | pt |
dc.date.embargo | 2020-10-27 | * |
uc.date.periodoEmbargo | 0 | pt |
item.openairetype | article | - |
item.fulltext | Com Texto completo | - |
item.languageiso639-1 | en | - |
item.grantfulltext | open | - |
item.cerifentitytype | Publications | - |
item.openairecristype | http://purl.org/coar/resource_type/c_18cf | - |
crisitem.author.researchunit | CQC - Coimbra Chemistry Centre | - |
crisitem.author.parentresearchunit | Faculty of Sciences and Technology | - |
crisitem.author.orcid | 0000-0003-0624-8819 | - |
Appears in Collections: | I&D CQC - Artigos em Revistas Internacionais |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
Regulatory-approval-of-photoimmunotherapy-photodynamic-therapy-that-induces-immunogenic-cell-deathOncoImmunology.pdf | 1.05 MB | Adobe PDF | View/Open |
Page view(s)
51
checked on Jul 17, 2024
Download(s)
31
checked on Jul 17, 2024
Google ScholarTM
Check
Altmetric
Altmetric
This item is licensed under a Creative Commons License